Scinai Immunotherapeutics (SCNI) Long-Term Deferred Tax (2021 - 2025)

Scinai Immunotherapeutics (SCNI) has 5 years of Long-Term Deferred Tax data on file, last reported at $28.1 million in Q4 2025.

• For the quarter ending Q4 2025, Long-Term Deferred Tax rose 20.24% year-over-year to $28.1 million; the trailing twelve-month figure through Dec 2025 stood at $28.1 million (up 20.24% YoY), and the FY2025 full-year result was $28.1 million, up 20.24% from the prior year.
• Long-Term Deferred Tax rose to $28.1 million in Q4 2025, from $23.4 million in the prior quarter.
• In the past five years, Long-Term Deferred Tax ranged from a high of $28.1 million in Q4 2025 to a low of $19.6 million in Q4 2021.
• A 5-year average of $23.8 million and a median of $23.4 million in 2024 frame the typical range for Long-Term Deferred Tax.
• Across the five-year window, Long-Term Deferred Tax declined 10.46% in 2024 and climbed 20.24% in 2025, its largest moves.
• Tracing SCNI's Long-Term Deferred Tax over 5 years: stood at $19.6 million in 2021, then grew by 12.52% to $22.0 million in 2022, then gained by 18.56% to $26.1 million in 2023, then fell by 10.46% to $23.4 million in 2024, then increased by 20.24% to $28.1 million in 2025.
• Business Quant data shows SCNI's Long-Term Deferred Tax at $28.1 million in Q4 2025, $23.4 million in Q4 2024, and $26.1 million in Q4 2023.